GlassScriptPhysician profile
Lisa Coker
NPI 1265986913
$7,649.88
in general payments reported to CMS, 2019-2025
26 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $734 · 2022: $1,141 · 2023: $1,742 · 2024: $1,953 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,727 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,726.81 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,148.88 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $1,092.81 | 2021-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $665.96 | 2021-2025 | Rayaldee |
| Horizon Therapeutics Plc | $664.41 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $623.16 | 2021-2025 | |
| Travere Therapeutics, INC. | $390.96 | 2023-2025 | Filspari |
| Ardelyx, INC. | $386.94 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.96 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $319.74 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $282.72 | 2021-2025 | Benlysta |
| Novo Nordisk INC | $278.24 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $271.59 | 2023-2025 | |
| Vifor Pharma, INC. | $250.90 | 2021-2023 | Korsuva, Veltassa |
| Fresenius USA Marketing, INC. | $208.07 | 2022-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $172.89 | 2023-2025 | Tarpeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $144.97 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $77.74 | 2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $69.60 | 2021-2024 | Jynarque |
| Janssen Pharmaceuticals, INC | $66.32 | 2024 | Xarelto |
| Akebia Therapeutics INC | $43.37 | 2021-2025 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $39.64 | 2023 | Gattex |
| Ultragenyx Pharmaceutical INC. | $28.51 | 2023 | |
| Abbvie INC. | $21.63 | 2021 | |
| Bard Peripheral Vascular, INC. | $20.99 | 2022 | |
| Ascendis Pharma Endocrinology INC | $17.14 | 2025 | Yorvipath |
| Pharmacosmos Therapeutics INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Coker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.